

<sup>14</sup>  
57. (Amended) The method of claim <sup>1</sup>42, wherein the immunostimulatory nucleic acid comprises a nucleotide sequence selected from the group of the following nucleotide sequences TCCATGTCGCTCCTGATGCT (SEQ ID NO:37), TCCATAACG TTCCTGATGCT (SEQ ID NO:3), TCCATGACGATCCTGATGCT (SEQ ID NO:87), TCCATGACGTCCCTGATGCT (SEQ ID NO:39), TCCATGTCG TTCCTGATGCT (SEQ ID NO:38), TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID NO:46), TCGTCGTTGTCGTTGTCGTT (SEQ ID NO:47), TCCATGACGGTCCTGATGCT (SEQ ID NO:35), TCCATGACGCTCCTGATGCT (SEQ ID NO:88), TCCATGACG TTCCTGATGCT (SEQ ID NO:7), TCCATCACGTGCCTGATGCT (SEQ ID NO:40), TCGTCGTTGTCGTTTTGTCGTT (SEQ ID NO:49), GCGTGCGTTGTCGTTGTCGTT (SEQ ID NO:56), TGTCGTTTGTGCGTTTGTGCGTT (SEQ ID NO:48), TGTCGTTGTCGTTGTCGTT (SEQ ID NO:50), TCGTCGTGTCGTT (SEQ ID NO:51), TCCTGTGCTTCCTTGTGCGTT (SEQ ID NO:52), TCCTGTGCTTTTTTGTGCGTT (SEQ ID NO:53), TCGTCGCTGTCTGCCCTTCTT (SEQ ID NO:54), and TCGTCGCTGTTGTCGTTTCTT (SEQ ID NO:55).

<sup>15</sup>  
58. (Amended) The method of claim <sup>1</sup>42, wherein the immunostimulatory nucleic acid comprises the following nucleotide sequence TCCATGTCGCTCCTGATGCT (SEQ ID NO:37).

<sup>16</sup>  
59. (Amended) The method of claim <sup>1</sup>42, wherein the immunostimulatory nucleic acid comprises the following nucleotide sequence TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID NO:46).

<sup>35</sup>  
60. (Amended) The method of claim <sup>20</sup>60, further comprising administering an adjuvant.

<sup>37</sup>  
61. (Amended) The method of claim <sup>20</sup>60, wherein the immunostimulatory nucleic acid comprises a nucleotide sequence selected from the group of the following nucleotide sequences TCCATGTCGCTCCTGATGCT (SEQ ID NO:37), TCCATAACG TTCCTGATGCT (SEQ ID NO:3), TCCATGACGATCCTGATGCT (SEQ ID NO:87), TCCATGACGTCCCTGATGCT

(SEQ ID NO:39), TCCATGTCGTTCCCTGATGCT (SEQ ID NO:38),  
TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID NO:46), TCGTCGTTGTCGTTGTCGTT  
(SEQ ID NO:47), TCCATGACGGTCCTGATGCT (SEQ ID NO:35),  
TCCATGACGCTCCTGATGCT (SEQ ID NO:88), TCCATGACGTTCCCTGATGCT (SEQ ID  
NO:7), TCCATCACGTGCCTGATGCT (SEQ ID NO:40), TCGTCGTTGTCGTTTTGTCGTT  
(SEQ ID NO:49), GCGTGCGTTGTCGTTGTCGTT (SEQ ID NO:56),  
TGTCGTTTGTGCGTTTGTGCGTT (SEQ ID NO:48), TGTCGTTGTCGTTGTCGTT (SEQ ID  
NO:50), TCGTCGTCGTCGTT (SEQ ID NO:51), TCCTGTCGTTCCCTGTCGTT (SEQ ID  
NO:52), TCCTGTCGTTTTTTGTCGTT (SEQ ID NO:53), TCGTCGCTGTCTGCCCTTCTT  
(SEQ ID NO:54), and TCGTCGCTGTTGTCGTTTCTT (SEQ ID NO:55).

E3  
cont

<sup>34</sup>  
80. (Amended) The method of claim <sup>20</sup>~~80~~, wherein the immunostimulatory nucleic acid  
comprises the following nucleotide sequence TCCATGTCGCTCCTGATGCT (SEQ ID  
NO:37).

<sup>39</sup>  
81. (Amended) The method of claim <sup>20</sup>~~80~~, wherein the immunostimulatory nucleic acid  
comprises the following nucleotide sequence TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID  
NO:46).

<sup>44</sup>  
82. (Amended) A method for treating asthma in a subject, comprising  
administering to an asthmatic subject an effective amount for treating asthma in a  
subject of an immunostimulatory nucleic acid, wherein the immunostimulatory nucleic acid  
comprises a nucleotide sequence selected from the group of the following nucleotide sequences  
TCCATGTCGATCCTGATGCT (SEQ ID NO:36), TCCATGTCGGTCCTGATGCT (SEQ ID  
NO:28), and GGGGTCAACGTTGAGGGGGG (SEQ ID NO:12).

✓

✓

<sup>44</sup>  
85. (Amended) The method of claim <sup>44</sup>~~82~~, wherein the immunostimulatory nucleic acid  
comprises the following nucleotide sequence GGGGTCAACGTTGAGGGGGG (SEQ ID  
NO:12).

E4

108

A